The 7th Haemophilia Global Summit was held in Madrid, Spain, in September 2016.
patients on treatment, bleeding episodes and goals of treatment as discussed by Professor Cedric Hermans (Table 1 ).
| Haemophilia care before birth
For a majority of patients, the start of this lifelong patient-healthcare team relationship begins with the assessment of potential carriers of haemophilia. Counselling and genetic testing should ideally take place before pregnancy is considered and should be reviewed with the patient and obstetric teams during the prenatal phase -a topic explored by Dr Roseline d'Oiron (France).
However, a lack of standardised screening programmes globally means that, even in the Western World, significant numbers of patients remain unaware of their carrier status during the first pregnancy (up to 91% of carriers in the USA 2 and 31% in the Netherlands 3 ).
The benefits of identification of carriers before pregnancy include the opportunity for providing support for genetic counselling, as well as a detailed discussion on the range of options available to women including pre-implantation genetic procedures. 
| Haemophilia care in the era of information technology
The ability to self-administer treatment at home has changed the face of haemophilia care, and significantly improved outcomes for people with haemophilia. 5 However, this transition of infusion responsibility from the haemophilia centre to the family/patient has also brought with it challenges in monitoring adherence, factor usage and bleeding frequency. 6 At the same time, advances in the field of information technology are changing the face of our daily lives, with opportunities to apply technological advances to the field of medicine. In the field of haemophilia, these advances are being applied to applications and initiatives designed to support the daily lives of people with haemophilia, including digital monitoring via apps and smart devices that "talk" to the clinic, alerts reminding patients to administer their treatment, online forums for education and sharing of information and improved communication between patients and their care team. 6 In the rapidly advancing field of digital healthcare, it is important to ensure the patient remains at the centre of the latest advances. The 7th Haemophilia Global Summit provided an opportunity for Dr Dan
Hart (UK) and Marlies Schrijvers (the Netherlands) to share examples of innovative digital support tools from their countries, and challenge delegates to consider these and other initiatives.
The "My Haemophilia Centre" mobile app, developed in collaboration with the Royal London Hospital and supported by funding from
Pfizer, provides patients with easily accessible and relevant information about both their condition and their local haemophilia centre.
The app is customised to the individual haemophilia treatment centre to provide practical support services and up-to-the-minute advice to patients and their families. The "Haemophilia Challenged" selfmanagement programme for people with haemophilia (PWH) in the Netherlands has been developed with the help of patients to provide online training and support for PWH in an easy-to-understand format.
Delegates were encouraged to work with patients in their centres to understand further their specific needs, and develop bespoke online and mobile services to provide practical, day-to-day support to their local haemophilia community.
| Managing haemophilia in older age
Continuing the theme of the value of nurturing and maintaining relationships between the patient and multidisciplinary care team, Dr Gerry Dolan (UK) sought to explore further the evolution of this relationship over time, into older age.
Although data on the management of comorbidities in older peo- | 5
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On a more practical level, inactivity/lack of activity has long been recognised as an important risk factor for cardiovascular disease and other serious medical conditions. Ensuring that people with haemophilia maintain an active, healthy lifestyle to avoid obesity and to support joint health through appropriate forms of exercise should be a focus of treatment throughout all life stages.
| MODERN HAEMOPHILIA CARE: SAFETY CONSIDERATIONS IN CLOTTING FACTOR CHOICE
Advances in manufacturing have led to the development of a range of clotting factor concentrate (CFC) treatment options representing the highest levels of purity and safety we have seen to date in the field of haemophilia. 10 Today, development of inhibitors is considered the most significant complication of haemophilia care. 11 A clear understanding of the data on product characteristics and the range of clinical evidence on efficacy and safety, including potential risk of infection and inhibitor development, is key to ensuring informed decision-making for parents, patients and physicians.
| Inhibitors in haemophilia A and B
With this in mind, Dr Dan Hart (UK) and Professor Jan Astermark consequently, the data on inhibitor management are limited. 13 An additional issue in haemophilia B is that patients are exposed to much larger quantities of exogenous protein when treated with a standard dose of factor IX (FIX) CFC, compared with a standard dose of factor VIII (FVIII) CFC in haemophilia A. 14, 15 It is thought that this could explain the phenomenon of anaphylaxis and allergic reactions to factor IX concentrate in this population.
14 Immune tolerance induction (ITI) is the first-choice treatment for newly developed inhibitors. 16 However, not all patients have access to ITI, 17 and successful eradication of inhibitors is seen in only 60%-91% of patients with haemophilia A [18] [19] [20] and 31% of patients with haemophilia B. 21 It is unclear why some patients respond to ITI while others, including those with similar prognostic factors, show little to no response. 22 Not only is the success rate of ITI much lower in haemophilia B than in haemophilia A, but the risk of adverse events and allergic reactions is also much higher. 21 For example, of the 69% (11 of 16) of people with haemophilia B in the North American ITI registry in whom ITI therapy failed, 72.7% (8 of 11) had an adverse reaction and 36.4% (4 of 11) had allergic reactions. 21 Given the poor success rate of ITI in haemophilia B, alternative strategies should be explored.
One interesting approach has been described by Beutal and colleagues on an immunosuppressive protocol for haemophilia B with inhibitors, which includes intravenous immunoglobulins, dexamethasone and mycophenolate mofetil for resolution of both inhibitors and allergic reactions. 23 In addition, novel treatments are under investigation, such as the use of adjuvant immunomodulation in haemophilia A. 24 The future of inhibitor management using gene therapy 25 and/ or oral tolerance 26 in haemophilia B looks potentially more promising than for haemophilia A, but international collaboration is needed to investigate these novel approaches in such a small group of patients.
More registry data and clinical trials are urgently needed to inform strategies that both prevent and eradicate inhibitors in both haemophilia A and B.
| Haemophilia and inhibitor development: Focus on PUPs
Despite significant advances in our understanding of the mechanisms underlying haemophilia, debate continues regarding the relationship, if any, between clotting factor concentrate type and inhibitor development.
SIPPET (Survey of Inhibitors in Plasma-Product Exposed Toddlers), a recent multicentre, open-label study, randomised 251 previously untreated patients (PUPs) and minimally treated patients (MTPs) to receive plasma-derived factor VIII (pdFVIII) products containing von
Willebrand factor (vWF) or recombinant factor VIII (rFVIII). 27 The overall incidence of inhibitors was found to be significantly higher in the rFVIII arm than in the pdFVIII arm.
The results of the SIPPET study have been the topic of much debate since their publication, including published responses challenging the validity of the results and study methodology. 28, 29 Discussion continued during the 7th Haemophilia Global Summit,
where Drs Carmen Escuriola-Ettingshausen (Germany) and Robert Klamroth (Germany) accepted the challenge to debate whether or not the results of the SIPPET study should directly influence the future management of haemophilia in PUPs.
It is clear that this issue of risk of inhibitor by product type will continue to be studied. Any future studies should, like the SIPPET study, the first randomised study in this area, be critically assessed in the context of the totality of available data and clinical experience when making decisions about optimal treatment. In addition, parents and patients should be well informed and involved in treatment decisionmaking, where possible.
| Managing infection risk
With the increasing use of prophylaxis, the risk of pathogen exposure from plasma-derived CFCs increases over a patient's lifetime, with both the number of infusions and batch size of the plasma-derived product affecting the risk of exposure. 30 When considering choice of factor, it is worth noting that for many countries, there is very limited and sometimes no choice of CFC available for treatment. In this situation, treatment with available concentrates, manufactured to international standards, should be used. 31 For countries where choice does exist, consideration of potential transfusion-transmitted infection should be part of product choice.
| PRACTICAL APPROACHES TO HAEMOPHILIA CARE

| Pharmacokinetics in clinical practice
Current prophylactic regimens are based on a "one-size-fits-all" model that assumes the CFC half-life to be broadly similar for all patients. In fact, the clearance rate of CFC varies widely among patients because of multiple factors, including genotype, blood group, etc.
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Professor Hermans and Dr Dolan provided an overview of practical considerations for the application of personalised pharmacokinetics (PKs) in clinical practice. Knowledge of the individual PK of a patient's treatment enables precise adjustments of dosing and frequency to maintain adequate haemostatic levels and prevent bleeding. 34 In particular, the length of time a patient spends with "low" plasma factor levels is considered the main risk factor for breakthrough bleeding. 35 However, individual bleeding phenotype, in addition to patient lifestyle, varies according to the individual, and a fixed dosing regimen without consideration of individual PK variability may not provide optimal protection against bleeding. 36, 37 Measuring individual patient PKs in clinical practice can be timeconsuming and demanding on the patient, requiring a minimum of five samples and often an overnight stay in hospital. 33, 38 Advances in both our knowledge of the PKs of FVIII, and modelling techniques, are helping to improve our ability to offer personalised approaches based on PKs, at least in haemophilia A. For example, WAPPS-Hemo is a free web-based service that inputs several sample measurements as well as the patient's basic characteristics into a Bayesian analysis that considers the population average and returns individual PK estimates, including factor half-life and time to critical concentration. 39, 40 It is hoped that further improvements in PK modelling will not only help to individualise treatment to improve patient outcomes, but will also help to inform cost analysis as well as future research, particularly considering newer, extended half-life (EHL) molecules, for which detailed knowledge of a patient's individual PK will have great utility.
| Surgical considerations in haemophilia care and the prevention of joint damage
Over 70% of bleeding events in PWH occur in the joints (particularly the elbow, knee and ankle). 41 Bleeding events in the elbow, which typically begin at 2-5 years of age, can ultimately lead to chronic hypertrophic haemophilic synovitis, recurrent haemarthrosis and cartilage destruction, resulting in pain and limited motion of the joint, 42 and will often require surgical intervention in later life.
Professors Adolfo Llinás (Colombia) and Carlos Rodríguez-Merchán (Spain) provided a comprehensive review of management considerations for patients where surgical intervention is necessary. 
| HOW CAN WE MEASURE THE IMPACT OF HAEMOPHILIA THERAPY MORE EFFECTIVELY?
Although standard endpoints, such as annualised bleeding rates and joint health scores, can be used to assess treatment efficacy, these measures are variably applied in clinical practice and differentiating between treatments is becoming increasingly difficult. 49 Professor Mike Laffan (UK) addressed the question of how to measure the impact of haemophilia therapy more effectively noting that basic measures of peak and trough factor levels remain the simplest method. However, it is clear from clinical practice and the literature that patients on "standard" prophylactic regimens can still experience bleeding, despite maintaining "recommended" levels of FVIII. 50 Furthermore, as patients experience less bleeds, their expectations of life with haemophilia change and the pursuit of a "normal" life is seen as a reality for most patients. Managing patient expectations to achieve an active or "normal" lifestyle may require higher levels of CFC (or less time in the trough) for individuals to ensure a low bleeding risk. 37, 51 Therefore, purely targeting standard trough and peak levels of FVIII is probably not effective in all patients.
Considering joint health outcomes, although arthropathy has been
shown to decrease physical function and quality of life, 52 joint scores are not an ideal measure of outcomes as they often represent historical, irreversible damage and do not correlate well with current bleeding rates. 49, 53 Efficacy measures that can assess treatment effects at an individual level are needed, not only to achieve the best possible outcomes for every patient, but also to allow the measurement of meaningful outcomes in clinical trials. Annual bleed rate is commonly used as a measure of efficacy in clinical trials, but it may be unreliable. 54 Response to treatment often depends on current disease status and the patient's treatment goals, so outcome measures should be based on measurable benefits for each individual patient. 49, 54 Professor Margareth Ozelo (Brazil) additionally noted that a key challenge when designing clinical trials for bleeding disorders is the small number of patients with these diseases. 55 This is compounded by the large number of new areas of research in haemophilia, which creates competition for the small pool of possible participants. To date, most trials have been pre-or postauthorisation studies focused on the safety and efficacy of haemostatic products, [54] [55] [56] while well-designed studies investigating adequate dosing and prophylaxis, inhibitors, musculoskeletal outcomes and long-term follow-up of patients are lacking.
To improve the quality and range of clinical trials in haemophilia, treatment centres must be able to document a multitude of patient data for long-term studies.
Outcome measures that can discriminate treatment effects important to individual patients are needed in both clinical care and research. Initially, Manno et al. used AAV2 to deliver a high dose of the FIX gene to patients with severe haemophilia B. 59 At first, this produced a significant rise in FIX activity, but liver enzymes started to rise after 3 weeks, accompanied by a fall in FIX activity, which was subsequently shown to be the result of a cytotoxic T-cell response against the viral capsid of AAV2. 60 To overcome this, Nathwani and colleagues used a similar AAV delivery system, but used prednisolone to suppress the immune response. 61 Expression of FIX at 2%-11% of normal levels was observed in all participants, and four of the six participants could discontinue FIX prophylaxis. FIX expression of 1%-6% of the normal level persisted after 3.2 years, and a reduction of more than 90% in both bleeding episodes and prophylactic FIX use was shown at follow-up. 62 More recently, sustained expression of the FIX protein has been demonstrated by delivering a lower vector dose encoding a highactivity FIX Padua variant. 63, 64 Although significant progress has been made in the field of gene therapy for haemophilia B, haemophilia A poses a bigger challenge due to the larger size of the FVIII gene and potential immunogenicity. 58 However, development of a modified form of the gene or lentiviral vectors capable of carrying the large gene is being investigated as mechanisms to potentially overcome this problem. 58 An alternative approach to gene therapy is gene editing, which allows direct substitution of the faulty gene, leading to restoration of gene function under the control of the existing regulatory machinery. 65 Li et al. used AAV8 to deliver both a zinc finger nuclease (ZFN) and a human FIX cDNA cassette in a mouse model of haemophilia B. The ZFN induced a double-strand break at the hF9 locus, allowing insertion of the human FIX gene and resulting in sufficient FIX expression to recover normal clotting times. 65 Although these early results are promising, off-target effects are a concern when editing the genome and will require careful monitoring as studies progress.
| THE FUTURE OF HAEMOPHILIA CARE
| Gene therapy
| Will long-acting factors or gene therapy revolutionise delivery and standards of care in haemophilia?
Dr Manuel Carcao (Canada) provided an outline of the current range of investigational treatments expected to shape the haemophilia landscape over the coming years. Aside from gene therapy, alternative factor and non-factor treatments are also under investigation.
These investigational treatment avenues include factor substitutes, such as a humanised bispecific antibody that can mimic the cofactor function of FVIII and potentially avoid the risk of inhibitor development, 66 and non-factor therapies that rebalance haemostasis by reducing anticoagulant levels, such as tissue factor pathway inhibitor. 67 To what extent these novel treatment approaches will eventually change the future landscape of haemophilia care remains to be seen.
CONCLUSION
The management of haemophilia continues to improve, and the future of haemophilia care looks promising, with prophylaxis becoming the "gold standard" for both children and adults worldwide. 41 The development and management of inhibitors remain important areas for both clinical consideration and additional research. Looking to the future, optimal outcome measures need to be defined and welldesigned clinical trials, with input from multiple stakeholder groups, including healthcare providers, patient advocacy groups and industry, are required to investigate PK and dosing, inhibitors, musculoskeletal outcomes and long-term follow-up of patients.
With the evolution of our understanding of the science of haemophilia come innovations in digital healthcare and new treatment options, including novel treatments and gene therapy. However, it is worth remembering that these future innovations will reach patients at a different rate, depending on factors including their socioeconomic situation.
The Haemophilia Global Summit meeting series aims to provide a platform to support the exchange of evolving and emerging science with a focus on practical considerations and options for haemophilia care teams in resource-constrained environments. Through bringing together an international delegation of haemophilia experts to share their experiences and discuss practical approaches to the optimal management of haemophilia within developed and developing healthcare systems, we hope to support real-world advances in optimising care for people with haemophilia globally.
